Alan Alper's guest appearances

Alan Alper

Leveraging Thought Leadership

BackTable Vascular & Interventional

Everything Thought Leadership

Dorie Clark

Jon Levy

Kara Goldin

Mark Kenney

Michael Bungay Stanier

David Burkus

Ken Blanchard

Tom Peters

Jonathan Keyser

David Katz

David Komlos

David Benjamin

Niko Canner

Tom Schwab

Mark Goulston

OwlTail

Jawad Hussain

In this episode, our host Dr.Michael Barraza interviews Drs. Jawad Hussain and Alan Sag about how they implemented thyroid artery embolization into their respective private and academic practices.---CHECK OUT OUR SPONSORMedtronic Chocolate PTA Balloonhttps://www.medtronic.com/peripheral---EARN CMEReflect on how this Podcast applies to your day-to-day and earn free AMA PRA Category 1 CMEs: https://earnc.me/GXgzcZ---SHOW NOTESDr. Hussain discusses how he started doing thyroid embolizations. It was born out of a need to replace thyroid RFA, since the thyroid RFA generator was not yet approved in his health system. At Duke, Dr. Sag collaborated with endocrinologists and endocrine surgeons to address a need to treat non-surgical candidates with bulk symptoms. These symptoms can include supine dyspnea, dysphagia, and aspiration risk. Together, they developed an institutional protocol for post-procedural management. Dr. Sag emphasizes that everything an IR needs to perform a goiter embolization is probably already available to them.Next, the doctors describe how they implemented thyroid embolization in their respective practices. Dr. Sag approached his institution’s weekly tumor board of endocrine specialists to introduce the concept. When talking to non-surgical patients, he offers thyroid embolization as a palliation alternative to tracheostomy and percutaneous gastrostomy as airway protection for patients with aspiration risks. Dr. Hussain describes patients with TR-3 and TR-4 nodules who require repeat FNA. Embolization can be a valuable option for them, since it is a quick outpatient procedure with minimal side effects. Additionally, he communicates to patients that IRs have experience with applying transcatheter embolizations in different spaces in the body and sets the expectation that shrinkage will be a gradual process. Both doctors emphasize the importance of informed consent in a relatively new palliative procedure. In terms of the research landscape for thyroid embolization, Dr. Hussain says that publishing a large retrospective multicenter study would revolutionize the procedure, since it could show efficacy and safety. Dr. Sag believes that RFA and embolization are complementary technologies that can be used in different scenarios.Dr. Hussain shares his treatment algorithm, which includes getting a CTA after each consultation, to map out variable anatomy and select hypertrophied vessels. Deep cannulation is key to preventing reflux and non-target embolization. Additionally, he does a two week follow up for post-procedural symptoms and a 2 month imaging appointment. Dr. Sag describes a joint clinic with endocrine surgeons. Every patient gets a visit from each service on the same day, and the doctors are able to convene and make joint decisions based on patient and goiter factors. He recommends getting a cone beam CTA to rule out anastamoses to aerodigestive structures and the cervical spinal cord. In his embolization, he uses 300-500 micron Embospheres and leaves at least one quadrant untreated to spare some thyroid and parathyroid glands. He also administers decadron and a medrol dose pack. Lab follow-up happens at day 7, when most thyroid hormone peaks occur. If patients are still experiencing symptoms after two months, Dr. Sag will consider repeating the embolization.---RESOURCESThyroid Embolization for Nonsurgical Treatment of Nodular Goiter: A Single-Center Experience in 56 Consecutive Patients (Yilmaz et al):https://pubmed.ncbi.nlm.nih.gov/34256121/ACR TI-RADS:https://www.acr.org/Clinical-Resources/Reporting-and-Data-Systems/TI-RADS2017 Thyroid Radiofrequency Ablation Guideline: Korean Society of Thyroid Radiology:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6005940/

In this episode, our host Dr.Michael Barraza interviews Drs. Jawad Hussain and Alan Sag about how they implemented thyroid artery embolization into their respective private and academic practices. --- CHECK OUT OUR SPONSOR Medtronic Chocolate PTA Balloon<a href="https://www.medtronic.com/peripheral" rel="nofollow" target="_blank">https://www.medtronic.com/peripheral</a> --- EARN CME Reflect on how this Podcast applies to your day-to-day and earn free AMA PRA Category 1 CMEs: <a href="https://earnc.me/GXgzcZ" rel="nofollow" target="_blank">https://earnc.me/GXgzcZ</a> --- SHOW NOTES Dr. Hussain discusses how he started doing thyroid embolizations. It was born out of a need to replace thyroid RFA, since the thyroid RFA generator was not yet approved in his health system. At Duke, Dr. Sag collaborated with endocrinologists and endocrine surgeons to address a need to treat non-surgical candidates with bulk symptoms. These symptoms can include supine dyspnea, dysphagia, and aspiration risk. Together, they developed an institutional protocol for post-procedural management. Dr. Sag emphasizes that everything an IR needs to perform a goiter embolization is probably already available to them. Next, the doctors describe how they implemented thyroid embolization in their respective practices. Dr. Sag approached his institution’s weekly tumor board of endocrine specialists to introduce the concept. When talking to non-surgical patients, he offers thyroid embolization as a palliation alternative to tracheostomy and percutaneous gastrostomy as airway protection for patients with aspiration risks. Dr. Hussain describes patients with TR-3 and TR-4 nodules who require repeat FNA. Embolization can be a valuable option for them, since it is a quick outpatient procedure with minimal side effects. Additionally, he communicates to patients that IRs have experience with applying transcatheter embolizations in different spaces in the body and sets the expectation that shrinkage will be a gradual process. Both doctors emphasize the importance of informed consent in a relatively new palliative procedure. In terms of the research landscape for thyroid embolization, Dr. Hussain says that publishing a large retrospective multicenter study would revolutionize the procedure, since it could show efficacy and safety. Dr. Sag believes that RFA and embolization are complementary technologies that can be used in different scenarios. Dr. Hussain shares his treatment algorithm, which includes getting a CTA after each consultation, to map out variable anatomy and select hypertrophied vessels. Deep cannulation is key to preventing reflux and non-target embolization. Additionally, he does a two week follow up for post-procedural symptoms and a 2 month imaging appointment. Dr. Sag describes a joint clinic with endocrine surgeons. Every patient gets a visit from each service on the same day, and the doctors are able to convene and make joint decisions based on patient and goiter factors. He recommends getting a cone beam CTA to rule out anastamoses to aerodigestive structures and the cervical spinal cord. In his embolization, he uses 300-500 micron Embospheres and leaves at least one quadrant untreated to spare some thyroid and parathyroid glands. He also administers decadron and a medrol dose pack. Lab follow-up happens at day 7, when most thyroid hormone peaks occur. If patients are still experiencing symptoms after two months, Dr. Sag will consider repeating the embolization. --- RESOURCES Thyroid Embolization for Nonsurgical Treatment of Nodular Goiter: A Single-Center Experience in 56 Consecutive Patients (Yilmaz et al):<a href="https://pubmed.ncbi.nlm.nih.gov/34256121/" rel="nofollow" target="_blank">https://pubmed.ncbi.nlm.nih.gov/34256121/</a> ACR TI-RADS:<a href="https://www.acr.org/Clinical-Resources/Reporting-and-Data-Systems/TI-RADS" rel="nofollow" target="_blank">https://www.acr.org/Clinical-Resources/Reporting-and-Data-Systems/TI-RADS</a> 2017 Thyroid Radiofrequency Ablation Guideline: Korean Society of Thyroid Radiology:<a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6005940/" rel="nofollow" target="_blank">https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6005940/</a>

Ep. 286 Minimally Invasive Thyroid Interventions with Dr. Jawad Hussain and Dr. Alan Alper Sag

Bob Buday

Buday Thought Leadership Partners is pleased to welcome Alan Alper to the company, as principal and chief operating officer. Alan helped take Cognizant Technology Solutions to new heights through his work in building a thought leadership function, where he was VP of Global Thought Leadership. Today, he joins Bob Buday to discuss his career in thought leadership, the future of the field, and what firms that compete on thought leadership must do to be recognized as top experts in their domains.Read more from the official post on Budaytlp.com: https://budaytlp.com/2022/03/01/alan-...

Buday Thought Leadership Partners is pleased to welcome Alan Alper to the company, as principal and chief operating officer. Alan helped take Cognizant Technology Solutions to new heights through his work in building a thought leadership function, where he was VP of Global Thought Leadership. Today, he joins Bob Buday to discuss his career in thought leadership, the future of the field, and what firms that compete on thought leadership must do to be recognized as top experts in their domains. Read more from the official post on <a href="http://Budaytlp.com" rel="nofollow" target="_blank">Budaytlp.com</a>: <a href="https://budaytlp.com/2022/03/01/alan-" rel="nofollow" target="_blank">https://budaytlp.com/2022/03/01/alan-</a>...

Everything Thought Leadership – Building the Go-To Thought Leadership Firm: Bob Buday and Alan Alper

Peter Winick

A lot of thought leaders wonder how to align their thought leadership to business metrics, and what it looks like to achieve "success" with your thought leadership. If it's crossed your mind, then this is the episode for you! We interviewed  Alan Alper, V.P. of corporate marketing and global thought leadership programs at Cognizant Technology Solutions, which is a global I.T. consulting and business services company. Alan’s work with organizational thought leadership is groundbreaking, and helping to forge new standards for content marketing in major organizations worldwide. He talks about ways to give your thought leadership a credible foundation, why sharing your thought leadership content for free can increase your business, and why he created a "Blue-Ribbon Panel" of the best and brightest thought leadership within his organization. Listen in, and learn more!

A lot of thought leaders wonder how to align their thought leadership to business metrics, and what it looks like to achieve "success" with your thought leadership. If it's crossed your mind, then this is the episode for you! We interviewed <a href="https://www.linkedin.com/in/alan-alper-9669b/" rel="noopener nofollow" target="_blank"> Alan Alper</a>, V.P. of corporate marketing and global thought leadership programs at <a href="https://www.cognizant.com/canada" rel="noopener nofollow" target="_blank">Cognizant Technology Solutions</a>, which is a global I.T. consulting and business services company. Alan’s work with organizational thought leadership is groundbreaking, and helping to forge new standards for content marketing in major organizations worldwide. He talks about ways to give your thought leadership a credible foundation, why sharing your thought leadership content for free can increase your business, and why he created a "Blue-Ribbon Panel" of the best and brightest thought leadership within his organization. Listen in, and learn more!

Leveraging Thought Leadership | Alan Alper | 210